Sugimoto J, Wasaki M, Inoue Y, Shirota K, Nomura Y
Mitsubishi Chemical Corporation, Yokohama Research Center, Japan.
Toxicol Pathol. 1996 Sep-Oct;24(5):627-35. doi: 10.1177/019262339602400514.
There have been a few studies on canine nephrotoxic glomerulonephritis produced by anti-glomerular basement membrane serum (AGBM), but these reports have not focused on an alteration in the charge properties of glomerular basement membrane (GBM). In this study, rabbit AGBM or normal rabbit serum (NRS) was given intravenously (2 ml/kg body weight) to 16 male beagle dogs. An alteration of anionic sites (ASs) of GBM was studied quantitatively using polyethyleneimine as a cationic probe by electron microscopy at weeks 1, 2, 4, and 8 postinjection. In AGBM-treated dogs, severe or mild proteinuria continued until week 2. At weeks 4 and 8, there was no significant difference in the intensity of proteinuria between AGBM- and NRS-treated groups. Until week 2 postinjection, there were significantly fewer ASs of GBM in AGBM-treated dogs than in NRS-treated dogs. At week 8, however, there was no difference in ASs of GBM between AGBM- and NRS-treated dogs. The fact that a reduction of glomerular AS occurred in AGBM-treated dogs with severe or mild proteinuria and the recovery of AS in the GBM coincided with an improvement of proteinuria suggested that alteration of the glomerular ASs might play an important role in the pathogenesis of proteinuria in canine anti-GBM nephritis.
已经有一些关于抗肾小球基底膜血清（AGBM）诱发犬肾毒性肾小球肾炎的研究，但这些报告并未聚焦于肾小球基底膜（GBM）电荷特性的改变。在本研究中，给16只雄性比格犬静脉注射兔AGBM或正常兔血清（NRS）（2 ml/kg体重）。在注射后第1、2、4和8周，通过电子显微镜，以聚乙烯亚胺作为阳离子探针，定量研究GBM阴离子位点（ASs）的改变。在接受AGBM治疗的犬中，严重或轻度蛋白尿持续至第2周。在第4周和第8周，AGBM治疗组和NRS治疗组之间蛋白尿强度无显著差异。在注射后第2周之前，接受AGBM治疗的犬GBM的ASs明显少于接受NRS治疗的犬。然而，在第8周，AGBM治疗组和NRS治疗组犬GBM的ASs没有差异。在有严重或轻度蛋白尿的AGBM治疗犬中出现肾小球ASs减少，且GBM中ASs的恢复与蛋白尿改善同时发生，这一事实表明，肾小球ASs的改变可能在犬抗GBM肾炎蛋白尿的发病机制中起重要作用。
